Literature DB >> 32748649

Daily and near-daily cannabis use is associated with HIV viral load suppression in people living with HIV who use cocaine.

Deepika E Slawek1,2, Julia Arnsten1,2, Nancy Sohler3, Chenshu Zhang2, Robert Grossberg1,2, Melissa Stein1,2, Chinazo O Cunningham1,2.   

Abstract

Disparities remain in HIV viral load (VL) suppression between people living with HIV (PLWH) who use cocaine and those who do not. It is not known how cannabis use affects VL suppression in PLWH who use cocaine. We evaluated the relationship between cannabis use and VL suppression among PLWH who use cocaine. We conducted a secondary data analysis of 119 baseline interviews from a randomized controlled trial in the Bronx, NY (6/2012 to 1/2017). Participants were adult PLWH prescribed antiretrovirals for ≥16 weeks, who endorsed imperfect antiretroviral adherence and used cocaine in the past 30-days. In bivariate and multivariable regression analyses, we examined how cannabis use, is associated with VL suppression among PLWH who use cocaine. Participants were a mean age of 50 years; most were male (64%) and non-Hispanic black (55%). Participants with VL suppression used cocaine less frequently than those with no VL suppression (p < 0.01); cannabis use was not significantly different. In regression analysis, compared with no use, daily/near-daily cannabis use was associated with VL suppression (aOR = 4.2, 95% CI: 1.1-16.6, p < 0.05). Less-frequent cannabis use was not associated with VL suppression. Further investigation is needed to understand how cannabis use impacts HIV outcomes among PLWH who use cocaine.

Entities:  

Keywords:  HIV; cannabis; cocaine; substance use; viral suppression

Mesh:

Substances:

Year:  2020        PMID: 32748649      PMCID: PMC7858684          DOI: 10.1080/09540121.2020.1799922

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  44 in total

1.  Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women.

Authors:  Tanya Telfair Sharpe; Lisa M Lee; Allyn K Nakashima; Laurie D Elam-Evans; Patricia L Fleming
Journal:  J Community Health       Date:  2004-04

2.  Drug use and medication adherence among HIV-1 infected individuals.

Authors:  Charles H Hinkin; Terry R Barclay; Steven A Castellon; Andrew J Levine; Ramani S Durvasula; Sarah D Marion; Hector F Myers; Douglas Longshore
Journal:  AIDS Behav       Date:  2007-03

3.  Medicinal and recreational marijuana use among HIV-infected women in the Women's Interagency HIV Study (WIHS) cohort, 1994-2010.

Authors:  Gypsyamber Dʼsouza; Pamela A Matson; Cynthia D Grady; Shadi Nahvi; Dan Merenstein; Kathleen M Weber; Ruth Greenblatt; Pam Burian; Tracey E Wilson
Journal:  J Acquir Immune Defic Syndr       Date:  2012-12-15       Impact factor: 3.731

4.  Marijuana use and its association with adherence to antiretroviral therapy among HIV-infected persons with moderate to severe nausea.

Authors:  Bouke C de Jong; Diane Prentiss; Willi McFarland; Rhoderick Machekano; Dennis M Israelski
Journal:  J Acquir Immune Defic Syndr       Date:  2005-01-01       Impact factor: 3.731

5.  Acute Illness Associated With Cannabis Use, by Route of Exposure: An Observational Study.

Authors:  Andrew A Monte; Shelby K Shelton; Eleanor Mills; Jessica Saben; Andrew Hopkinson; Brandon Sonn; Michael Devivo; Tae Chang; Jacob Fox; Cody Brevik; Kayla Williamson; Diana Abbott
Journal:  Ann Intern Med       Date:  2019-03-26       Impact factor: 25.391

6.  Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic.

Authors:  Gregory M Lucas; Kelly A Gebo; Richard E Chaisson; Richard D Moore
Journal:  AIDS       Date:  2002-03-29       Impact factor: 4.177

7.  Adherence, drug use, and treatment failure in a methadone-clinic-based program of directly administered antiretroviral therapy.

Authors:  Gregory M Lucas; B Anna Mullen; Mary E McCaul; Paul J Weidle; Shannon Hader; Richard D Moore
Journal:  AIDS Patient Care STDS       Date:  2007-08       Impact factor: 5.078

8.  The Fifth Edition of the Addiction Severity Index.

Authors:  A T McLellan; H Kushner; D Metzger; R Peters; I Smith; G Grissom; H Pettinati; M Argeriou
Journal:  J Subst Abuse Treat       Date:  1992

9.  Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats.

Authors:  Linda A Parker; Page Burton; Robert E Sorge; Christine Yakiwchuk; Raphael Mechoulam
Journal:  Psychopharmacology (Berl)       Date:  2004-09       Impact factor: 4.530

10.  Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: The impact of contextual factors.

Authors:  Philippe Lucas; Zach Walsh; Kim Crosby; Robert Callaway; Lynne Belle-Isle; Robert Kay; Rielle Capler; Susan Holtzman
Journal:  Drug Alcohol Rev       Date:  2015-09-14
View more
  4 in total

1.  Increasing Access to Safe Medical Cannabis: Establishment of a Medical Cannabis Program in a Safety-Net Academic Medical Center.

Authors:  Jonathan Ross; Jaclyn Yamada; Deepika Slawek; Joanna L Starrels; Chinazo O Cunningham; Julia H Arnsten
Journal:  NEJM Catal Innov Care Deliv       Date:  2022-01-19

2.  Self-Reported Cannabis Use and HIV Viral Control among Patients with HIV Engaged in Care: Results from a National Cohort Study.

Authors:  Anees Bahji; Yu Li; Rachel Vickers-Smith; Stephen Crystal; Robert D Kerns; Kirsha S Gordon; Alexandria Macmadu; Melissa Skanderson; Kaku So-Armah; Minhee L Sung; Fiona Bhondoekhan; Brandon D L Marshall; E Jennifer Edelman
Journal:  Int J Environ Res Public Health       Date:  2022-05-06       Impact factor: 4.614

Review 3.  Mini-review: The therapeutic role of cannabinoids in neuroHIV.

Authors:  Barkha J Yadav-Samudrala; Sylvia Fitting
Journal:  Neurosci Lett       Date:  2021-02-12       Impact factor: 3.046

Review 4.  Confound, Cause, or Cure: The Effect of Cannabinoids on HIV-Associated Neurological Sequelae.

Authors:  Alexander Starr; Kelly L Jordan-Sciutto; Eugene Mironets
Journal:  Viruses       Date:  2021-06-26       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.